Every Form 4 that Curis (CRIS) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CRIS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CRIS filings page.
Curis Inc. director Marc Rubin received a grant of stock options. He was awarded non-qualified options covering 6,800 shares of Curis common stock at an exercise price of $5.29 per share. The options vest 100% on July 7, 2027 and expire on July 6, 2036.
CURIS INC director Kenneth I. Kaitin reported receiving a grant of non-qualified stock options linked to the company’s common stock. The award covers 6,800 options with an exercise price of $5.29 per share, giving the right to acquire 6,800 shares of common stock.
The options vest as to 100% of the underlying shares on July 7, 2027 and carry an expiration date of July 6, 2036. Following this grant, the filing shows 6,800 derivative securities held directly, reflecting a routine compensation-related equity award rather than an open-market stock purchase or sale.
CURIS INC director John Hohneker received a grant of 6,800 non-qualified stock options with an exercise price of $5.29 per share. These options relate to 6,800 shares of common stock and were awarded as a grant or other acquisition, not an open-market purchase or sale.
The options vest as to 100% of the underlying shares on July 7, 2027, and are scheduled to expire on July 6, 2036. Following this award, Hohneker holds 6,800 derivative securities directly in the form of these options.
CURIS INC director Martyn D. Greenacre received a grant of options on 6,800 shares of common stock. These non-qualified stock options have an exercise price of $5.29 per share and expire on July 6, 2036. The options vest 100% on July 7, 2027, aligning compensation with longer-term performance.
CURIS INC director Anne Elizabeth Borgman received a grant of non-qualified stock options, acquiring rights to purchase 6,800 shares of common stock at an exercise price of $5.29 per share. These options vest 100% on July 7, 2027 and expire on July 6, 2036. Following this grant, her reported derivative holdings from this award total 6,800 options, reflecting compensation-related equity rather than an open-market purchase.
CURIS INC CFO Diantha Duvall received an employee stock option grant covering 48,285 shares of common stock at an exercise price of $5.29 per share. This is a compensation-related award, not an open-market stock purchase or sale.
The option vests over time, with 25% of the original shares vesting on July 7, 2027, and an additional 6.25% vesting each quarter until July 7, 2030. The option expires on July 6, 2036 if not exercised.
CURIS INC Chief Development Officer Jonathan B. Zung received a grant of employee stock options covering 48,285 shares of common stock at an exercise price of $5.29 per share. These options expire on July 6, 2036 and represent his entire reported option position in this filing.
The grant vests over time. According to the terms, 25% of the original option shares vest on July 7, 2027, with an additional 6.25% vesting each successive quarter until July 7, 2030. This structure ties a significant portion of his compensation to the company’s long-term stock performance.
CURIS INC President & CEO James E. Dentzer reported a compensation-related grant of employee stock options. He was awarded options to buy 110,090 shares of Curis common stock at an exercise price of $5.29 per share, expiring on July 6, 2036.
According to the filing, 25% of the original option shares vest on July 7, 2027, with an additional 6.25% of the original shares vesting each successive quarter until July 7, 2030. Following this grant, Dentzer holds options covering 110,090 underlying shares directly.
Curis Inc. director Kenneth I. Kaitin reported an open-market purchase of 10,000 shares of Curis common stock at $0.5487 per share. After this transaction, his direct ownership increased to 11,407 shares, indicating a meaningful addition relative to his prior holdings.
CURIS INC CDO Jonathan B. Zung converted preferred stock into common shares. On March 20, 2026, he converted 50 shares of Series B Convertible Preferred Stock into 66,667 shares of common stock for no additional cash consideration. Following the conversion, he holds 66,667 common shares directly.
Curis Inc. Chief Medical Officer Ahmed Hamdy converted preferred stock into common shares. On March 20, 2026, 50 shares of Series B Convertible Preferred Stock were converted into 66,667 shares of common stock for no additional consideration, leaving no Series B Preferred outstanding for him and 66,667 common shares held directly.
CURIS INC CFO Diantha Duvall converted preferred stock into common shares. On March 20, 2026, 50 shares of Series B Convertible Preferred Stock automatically converted into 66,666 shares of Common Stock for no additional consideration, increasing her direct common stock holdings to 77,707 shares.
Each share of Series B Preferred Stock converts into 1,333.33 common shares under the company’s Certificate of Designations and is subject to specified beneficial ownership limitations. This filing reflects an internal capital structure change for the executive rather than an open‑market purchase or sale.
Curis Inc. reported that President & CEO James E. Dentzer converted preferred shares into common stock. On March 20, 2026, he converted 100 shares of Series B Convertible Non-Redeemable Preferred Stock into 133,333 shares of common stock for no additional consideration through an automatic conversion.
After the conversion, Dentzer directly owned 148,730 shares of Curis common stock. Each Series B preferred share converted into 1,333.33 common shares, consistent with the terms described in the related certificate of designations and subject to specified beneficial ownership limitations.
Curis Inc director Marc Rubin converted preferred stock into common shares. On March 20, 2026, he converted 20 shares of Series B Convertible Preferred Stock into 26,667 shares of Common Stock for no additional consideration through an automatic conversion.
Following the conversion, Rubin directly owned 28,108 shares of Curis Common Stock. The preferred shares were originally sold as part of a $1,000.00 "Security" unit that also included Series A, B and C warrants, and converted subject to stated beneficial ownership limitations.
CURIS INC Chief Development Officer Jonathan B. Zung reported acquiring new equity-linked awards. He received 50 shares of Series B Convertible Preferred Stock, which automatically convert into 66,667 shares of Common Stock for no additional consideration at 5 p.m. Eastern Time on March 20, 2026, subject to Beneficial Ownership Limitations and other terms.
In connection with this, he also acquired Series A, Series B and Series C Warrants, each covering 66,667 shares of Common Stock at an exercise price of $0.75 per share. The warrants became immediately exercisable following receipt of requisite stockholder approval and a certificate of amendment filing on March 17, 2026, with the Series B Warrants featuring an exercise period tied to dosing milestones in a Phase 2 clinical trial of emavusertib.
Curis Inc’s CMO, Ahmed Hamdy, reported new equity-linked awards. He acquired 50 shares of Series B Convertible Preferred Stock, which automatically convert into 66,667 shares of common stock at 5 p.m. Eastern Time on March 20, 2026, subject to stated beneficial ownership limits.
He also received 66,667 Series A Warrants, 66,667 Series B Warrants and 66,667 Series C Warrants, each initially exercisable for common stock at an exercise price of $0.75 per share. The securities were sold at $1,000 per Security to him and became exercisable following requisite stockholder approval and a certificate of amendment filing. The Series B Warrants have a termination date tied to dosing the fifth patient in a Phase 2 emavusertib trial and may have their exercise price reset, within limits, if the stock trades below $0.75 at that time.
CURIS INC CFO Diantha Duvall received a grant of Series B Convertible Preferred Stock and multiple warrant series linked to Common Stock. On March 17, 2026, she acquired 50 shares of Series B Convertible Preferred Stock, which are set to automatically convert into 66,666 shares of Common Stock at 5 p.m. Eastern Time on March 20, 2026, subject to the terms of the Certificate of Designations and applicable Beneficial Ownership Limitations.
She was also granted 66,666 Series A Warrants, 66,666 Series B Warrants and 66,666 Series C Warrants, each exercisable for Common Stock with an exercise price of $0.75 per share. The Series A and Series C Warrants became immediately exercisable following receipt of Requisite Stockholder Approval and a Certificate of Amendment filing on March 17, 2026. The Series B Warrants became immediately exercisable on the same approval and will terminate 30 days after the company announces dosing of the fifth patient in a Phase 2 clinical trial, with provisions that may reset the exercise price and extend the termination date based on the Common Stock closing sale price at that time.
Curis Inc. President & CEO James E. Dentzer reported awards of preferred stock and warrants linked to Curis common shares. He received 100 shares of Series B Convertible Non-Redeemable Preferred Stock, with each preferred share automatically converting into 1,333.33 common shares for no additional consideration at 5 p.m. Eastern Time on March 20, 2026, subject to Beneficial Ownership Limitations.
He was also granted a Series A Warrant, a Series B Warrant and a Series C Warrant, each covering 133,333 shares of common stock at an exercise price of $0.75 per share and issued at no cost. The Series A and Series C Warrants became immediately exercisable after Requisite Stockholder Approval and a Certificate of Amendment filing on March 17, 2026. The Series B Warrants became immediately exercisable after the same approvals and will terminate 30 days after the company announces dosing of the fifth patient in its Phase 2 emavusertib trial, with a possible reset of the exercise price and a 30-day extension if the stock price is below $0.75 on that Initial Termination Date.
CURIS INC director Marc Rubin reported grants of new preferred stock and warrants linked to common shares. On March 17, 2026, he received 20 shares of Series B Convertible Preferred Stock, which automatically convert into 26,667 shares of common stock for no additional payment at 5 p.m. Eastern Time on March 20, 2026, subject to stated beneficial ownership limits.
He was also granted Series A, Series B and Series C warrants, each for 26,667 common shares at an exercise price of $0.75 per share. The Series A and Series C warrants became immediately exercisable upon receipt of required stockholder approval and a certificate of amendment filing, while the Series B warrants are exercisable on similar conditions but have a termination date tied to dosing milestones in a Phase 2 clinical trial and may have their exercise price reset and term extended based on the stock price at that milestone.